INVITING ALL MEMBERS OF THE MALAYSIAN SOCIETY OF HAEMATOLOGY
TO ATTEND THE 24TH WORLD CONGRESS OF PATHOLOGY & LABORATORY MEDICINE, 20TH-24TH AUGUST, 2007
The Congress has 5 concurrent streams of scientific programmes, one of which is devoted to haematology.
The Congress has one Presidential Symposium, one Keynote Lecture, 5 Plenary Lectures, 33 educational & scientific symposia and 5 corporate symposia. The Faculty comprises 112 international and local speakers.
A panel of international and local haematologists contribute to a full 3-day programme of updates in haematology.
The Congress would start off in the evening of 20th August, 2007 with a corporate symposium on recombinant Factor VIII. Professor Glenn Pierce (USA), Professor Lochie Teague (New Zealand) and Professor Alison Street (Australia) will speak in this symposium.
The next day (21st August, 2007):
In the symposium on new developments in myeloma management, Dr Gerrard Teoh (Singapore) would relate the pathogenesis of myeloma with insights from the clinical trial on dtZ treatment of myeloma; Prof John Gibson (Australia) would discuss the new and relevant investigations for the diagnosis and monitoring of myeloma; and Dr Soo-Chin Ng (Malaysia) would comment on whether newer agents for myeloma treatment are curative.
In the symposium on recent advances of blood cancers, Professor Y-L Kwong (Hong Kong) would review the diagnosis and treatment of natural killer cell malignancies, a neglected area where the haematologists have to deal with periodically; Professor Szu-Hee Lee (Australia) would propose a new way of looking at blast count for monitoring treatment of leukemias; and Dr Min-Hong Saw (Malaysia) would comment on whether low grade lymphoma are now curable with the advent of monoclonal antibody for therapy.
The following day (22nd August, 2007):
In the symposium on risk management of myeloproliferative disorders, Professor John Gibson (Australia) would explore the usefulness of the new WHO classification of myelodysplastic syndrome; Professor Jerry Spivak (USA) would assess the thrombotic risk in myeloproliferative disorders; and Professor Adrian Newland (Royal London, UK) would comment on whether we have been successful in overcoming blast crisis in chronic myeloid leukemia.
During lunch time, Dr Susan Brandford (Australia) would deliver a corporate lecture on molecular monitoring of chronic myeloid leukemia, touching on the recent developments and their significance.
In the symposium on new treatment strategies, Professor Herman Waldman (Oxford, UK) would relate how monoclonal antibodies are used to harness tolerance processes in transplantation and autoimmunity, an area which has benefited the haematologists tremendously; Professor Y-L Kwong (Hong Kong) would update us on the success of arsenic trioxide, an old drug which has found new use in cancer therapy; and Professor S-K Cheong (Malaysia) would update the audience on the expanding potential use of mesenchymal stem cells from the bone marrow and their embryonic stem cell-like properties, promising new agents for reparative medicine.
The last day (23rd August, 2007):
In the symposium on molecular genetics, Professor Suthat Fucharoen (Thailand) would talk about genetic modifiers in beta-thalassaemias, resulting in the diverse phenotypes of beta-thalassaemias; and Dr P Kuperan (Singapore) would explore the genetic polymorphism of warfarin resistance. You may then know why some patients need so little warfarin and others requiring a frightening high dose.
In a Plenary Lecture, Professor Herman Waldman (Oxford, UK) would give us the amazing history of CAMPATH-1 antibody; as you all know, he made this antibody while he was in Cambridge, UK, over 20 years ago.
In the concluding symposium, the audience would be treated to old problems new solutions in haematology. Professor Suthat Fucharoen (Thailand) would reveal new diagnostic techniques in haemoglobin disorders; Dr Shuichi Taniguchi (Toranomon Hospital, Japan) would surprise us on the successful use of cord blood transplantation in adults using the non-myeloablative approach; and Dr H Dharmendra (Malaysia) would update us on the recent development in cellular molecular imaging, an evolving field which could assist the haematologists in diagnosis, staging, prognostication and monitoring of blood cancers.
Announcment by
Prof S-K Cheong
Scientific Chairman.
Website: www.waspalm2007.org
